Transcenta Holding Ltd
Company Profile
Business description
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
Contact
B6-501, 218 Xinghu Street
Biobay
Suzhou215123
CHNT: +86 51267079200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
155
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
stocks
Ask the analyst: What to expect in earnings season?
stocks
ASX healthcare share remains undervalued ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,040.50 | 12.90 | 0.14% |
| CAC 40 | 8,372.28 | 0.00 | 0.00% |
| DAX 40 | 25,099.00 | 335.88 | 1.36% |
| Dow JONES (US) | 51,947.25 | 235.60 | 0.46% |
| FTSE 100 | 10,736.23 | 97.06 | 0.91% |
| HKSE | 25,143.55 | 180.32 | 0.72% |
| NASDAQ | 24,975.82 | 161.87 | -0.64% |
| Nikkei 225 | 64,764.01 | 152.86 | 0.24% |
| NZX 50 Index | 13,807.31 | 35.02 | 0.25% |
| S&P 500 | 7,411.98 | 3.68 | 0.05% |
| S&P/ASX 200 | 8,870.50 | 12.60 | 0.14% |
| SSE Composite Index | 3,826.70 | 12.50 | 0.33% |